Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immucor -- Ignore unavailable to you. Want to Upgrade?

To: Mason Barge who wrote (216)	9/23/1998 7:49:00 AM
From: Thomas Kirwin	Respond to of 422

ReACT Potential Mason, IMHO - Immucor fully understands the potential of ReACT as Dominion Biologicals distributes the product in Canada via a contract dated April '98. There may be other uses for the basic technology utilized in this device. A quick review of Gamma Biologicals 10-K reveals that they have over 100 individual products and were working on new products that could also add to Immucor's bottom line. Here is the link to Gamma's 10-K SEC filing dated June 29, 1998. sec.gov I agree that a money market account is a safe investment but it sure does not add value over the long term. Additionally, I believe that Immucor is utilizing some of Gamma's own cash to finance the purchase. They apparently did not have the full $25 million to invest. Don't forget the cash flow improvement. It is doubtful that Immucor will continue the dividend policy followed by Gamma. That's more cash! Our little company now has pro-forma revenues of nearly $60 million. The valuation of this company has improved based on this factor alone. The market seems to agree as the stock price sits at $10.00 Long & Strong Immucor! Tom

To: Mason Barge who wrote (216)	9/25/1998 7:45:00 AM
From: Thomas Kirwin	Read Replies (1) \| Respond to of 422

Shanghai Blood Center Sales I've located an article that provides a target date regarding Gamma Biological reagent sales to Shanghai Blood Center. "We are negotiating the first large order for bulk reagents. We could begin limited product shipments from the joint venture as early as September." amcity.com Regards, Tom